Compositions and methods for soft tissue augmentation

1. An injectable composition comprising isolated human elastin and a pharmaceutically acceptable carrier in solution, wherein said human elastin is isolated from human vascular tissue, which has not been frozen, by decellularizing the vascular tissue, exposing said decellularized tissue to a strong base and subsequently exposing the tissue to a primary alcohol and, wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa.

2. The composition of claim 1 , wherein the isolated human elastin is cross-linked.

3. The composition of claim 1 , wherein the composition comprises about 2 to about 60 mg/ml of isolated human elastin.

4. The composition of claim 1 , wherein the composition comprises about 3 to 30 mg/ml of isolated human elastin.

5. The composition of claim 1 , wherein the composition further comprises isolated human glycosaminoglycans.

6. The composition of claim 1 , wherein the composition further comprises adipose tissue.

7. The composition of claim 1 wherein the composition further comprises dermal fibroblasts.

8. The composition of claim 1 , wherein the composition further comprises one or more active agents selected from the group consisting of one or more anti-inflammatory agents, tissue formation agents, adipose tissue formation agents, anesthetics, antioxidants, heparin, epidermal growth factor, transforming growth factor, transforming growth factor-β, platelet-derived growth factor, fibroblast growth factor, connective tissue activating peptides, β-thromboglobulin, insulin-like growth factors, tumor necrosis factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factors, interferons or combinations thereof.

9. A dermal or subdermal filler comprising the composition of claim 1 .

10. The composition of claim 1 , wherein said elastin does not induce calcification in vivo in a human.

11. A kit for augmentation of a soft tissue comprising the composition of claim 1 , a syringe, a sterile wrapper surrounding said syringe and providing a sterile environment for said syringe.

12. The kit of claim 11 comprising agents selected from the group consisting of heparin, epidermal growth factor, transforming growth factor-alpha, transforming growth factor-beta, platelet-derived growth factor, fibroblast growth factor, connective tissue activating peptides, β-thromboglobulin, insulin-like growth factors, tumor necrosis factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factors, interferons, osteogenic factors and bone morphogenic proteins.

13. The composition of claim 1 , wherein said strong base is NaOH.

14. The composition of claim 1 , wherein said primary alcohol is ethanol.

15. The composition of claim 1 , wherein said human vascular tissue is human aorta.

16. The composition of claim 1 , further comprising isolated human collagen in a mixture with said isolated human elastin and said pharmaceutically acceptable carrier in solution.

17. The composition of claim 16 , wherein the isolated human collagen is isolated from micro-bead culture.

18. The composition of claim 16 , wherein the isolated human collagen has a molecular weight of about 100 to about 500 kDa.

19. The composition of claim 16 , wherein the composition comprises about 10-100 mg/ml of isolated human collagen.

20. The composition of claim 16 , wherein the composition comprises about 30 mg/ml of isolated human collagen.